Aitribond

ACC008 (Aitribond) is a once-daily, single-tablet fixed-dose combination regimen developed for the treatment of HIV-1 infection. It combines three active antiviral agents: ainuovirine (a novel, next-generation non-nucleoside reverse transcriptase inhibitor [NNRTI]), lamivudine (a nucleoside reverse transcriptase inhibitor [NRTI]), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor [NtRTI]). Originally developed by South Korea's Kainos Medicine as KM-023 and subsequently licensed to Jiangsu Aidea Pharmaceutical, ACC008 was approved in China in December 2022 for treatment-naïve HIV-1 patients and later expanded to treatment-experienced patients. Clinical studies, including the Phase III SPRINT trial, have demonstrated that ACC008 provides non-inferior virological suppression compared to standard regimens (such as Genvoya) while offering a more favorable lipid profile and reduced weight gain.